Epilepsy device pushes up Cyberonics sales
This article was originally published in Clinica
Executive Summary
Cyberonics, which markets an implantable vagus nerve stimulation device for epilepsy treatment, has recorded a 287% sales increase to $1.1 million in the first quarter. $554,000 of the sales were generated in the US, where the product, known as the NeuroCybernetic Prosthesis system, was launched this summer (see Clinica No 766, p 15).